Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases: an Indian perspective

Chaudhuri, Jasodhara; Biswas, Tanmay; Ganguly, Gautam; Datta, Supratim; Pandit, Alak; Biswas, Atanu

doi:10.1007/s13760-020-01356-9

Cited by 6 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Between 1999 and 2019, search results produced 99 articles related to “Neuromyelitis optica spectrum disorders”, “NMOSD”, “NMO”, “AQP4‐IgG”, “MOG‐IgG” AND India. After excluding reviews and case reports, 13 articles that described clinical, demographic features, investigations including testing for AQP4‐IgG and MOG‐IgG were included 39‐51 . These are listed chronologically in Table 2.…”

Section: Resultsmentioning

confidence: 99%

“…After excluding reviews and case reports, 13 articles that described clinical, demographic features, investigations including testing for AQP4-IgG and MOG-IgG were included. [39][40][41][42][43][44][45][46][47][48][49][50][51] These are listed chronologically in Table 2.…”

Section: Demographic and Clinical Features Of Nmosd In Indiamentioning

confidence: 99%

“…With the recent availability of commercial diagnostic kits (Euroimmun, Germany) for detection of AQP4-IgG & MOG-IgG, several papers have been published with definitive diagnosis of seropositive NMOSD from different parts of India. These included studies which described clinical features of AQP4-IgG-positive 39,40,45,46 and MOG-IgG-positive patients, 43,44,49,51 studies highlighting seroprevalence among patients with atypical demyelinating disorders 42 and comparative studies of demyelinating disorders from different regions of India. 48,50 Pediatric demyelinating disorders have been described from hospital settings.…”

Section: Demographic and Clinical Features Of Nmosd In Indiamentioning

confidence: 99%

See 2 more Smart Citations

Epidemiology and clinical features of demyelinating disorders in India

Pandit

Mustafa

2021

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

In tropical countries like India, noncommunicable diseases have traditionally received less priority over infectious diseases. In recent times, however, demyelinating disorders of the central nervous system have become recognized as an important group of noncommunicable neurological disorders in India. It is possible that increasing awareness among doctors on one hand and availability of magnetic resonance imaging facilities (MRI) in teaching and private hospitals in the metropolitan cities of India on the other have contributed to early diagnosis and treatment.The study of demyelinating disorders of the nervous system in India has been limited by many factors. Kurtzke's 1 epidemiological studies pointed to India as having a low prevalence for multiple sclerosis (MS). Neuromyelitis optica (NMO) was considered a variant of MS. In the pre-MRI era, diagnosis of MS centered around clinical

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Demographic and Clinical Features Of Nmosd In Indiamentioning

confidence: 99%

Section: Demographic and Clinical Features Of Nmosd In Indiamentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology and clinical features of demyelinating disorders in India

Pandit

Mustafa

2021

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

show abstract

“…Similar to NMOSD patients, at least 50% of MOGAD patients had a strong tendency to relapse (Jurynczyk et al, 2017;Kortvelyessy et al, 2017;Chaudhuri et al, 2021). ON is the most common clinical manifestation in patients with recurrent MOGAD (Cobo-Calvo et al, 2017;Wynford-Thomas et al, 2019;Chen et al, 2020).…”

Section: Relapsementioning

confidence: 88%

Clinical Features and Imaging Findings of Myelin Oligodendrocyte Glycoprotein-IgG-Associated Disorder (MOGAD)

Liu

Wang

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

Myelin oligodendrocyte glycoprotein-IgG-associated disorder (MOGAD) is a nervous system (NS) demyelination disease and a newly recognized distinct disease complicated with various diseases or symptoms; however, MOGAD was once considered a subset of neuromyelitis optica spectrum disorder (NMOSD). The detection of MOG-IgG has been greatly improved by the cell-based assay test method. In one study, 31% of NMOSD patients with negative aquaporin-4 (AQP-4) antibody were MOG-IgG positive. MOGAD occurs in approximately the fourth decade of a person’s life without a markedly female predominance. Usually, optic neuritis (ON), myelitis or acute disseminated encephalomyelitis (ADEM) encephalitis are the typical symptoms of MOGAD. MOG-IgG have been found in patients with peripheral neuropathy, teratoma, COVID-19 pneumonia, etc. Some studies have revealed the presence of brainstem lesions, encephalopathy or cortical encephalitis. Attention should be given to screening patients with atypical symptoms. Compared to NMOSD, MOGAD generally responds well to immunotherapy and has a good functional prognosis. Approximately 44-83% of patients undergo relapsing episodes within 8 months, which mostly involve the optic nerve, and persistently observed MOG-IgG and severe clinical performance may indicate a polyphasic course of illness. Currently, there is a lack of clinical randomized controlled trials on the treatment and prognosis of MOGAD. The purpose of this review is to discuss the clinical manifestations, imaging features, outcomes and prognosis of MOGAD.

show abstract

“…Twenty-two papers were finally excluded because of lack of sufficient clinical data provided or unconfirmed MOGAD diagnosis (eFigure 1 in online supplemental file 1). 11–32 As no randomised controlled clinical trials were found, only uncontrolled observational studies were included in the meta-analysis.…”

Section: Methodsmentioning

confidence: 99%

Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis

Spagni

Sun

Monte

et al. 2022

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

BackgroundRituximab (RTX) efficacy in patients with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorders (MOGADs) is still poorly understood, though it appears to be lower than in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders (AQP4-IgG+NMOSDs). The aim of this systematic review and meta-analysis is to assess the efficacy and safety profile of RTX in patients with MOGAD and to compare RTX efficacy between MOGAD and AQP4-IgG+NMOSD.MethodsWe searched original English-language articles published between 2012 and 2021 in MEDLINE, Cochrane, Central Register of Controlled Trials and clinicaltrials.gov, reporting data on RTX efficacy in patients with MOGAD. The main outcome measures were annualised relapse rate (ARR) and Expanded Disability Status Scale (EDSS) score mean differences (MDs) after RTX. The meta-analysis was performed with a random effects model. Covariates associated with the outcome measures were analysed with a linear meta-regression.ResultsThe systematic review included 315 patients (138 women, mean onset age 26.8 years) from 32 studies. Nineteen studies (282 patients) were included in the meta-analysis. After RTX, a significant decrease of ARR was found (MD: −0.92, 95% CI –1.24 to –0.60, p<0.001), markedly different from the AQP4-IgG+NMOSD (MD: −1.73 vs MOGAD −0.92, subgroup difference testing: Q=9.09, p=0.002). However, when controlling for the mean ARR pre-RTX, this difference was not significant. After RTX, the EDSS score decreased significantly (MD: −0.84, 95% CI −1.41 to –0.26, p=0.004). The frequency of RTX-related adverse events was 18.8% (36/192) and overall RTX-related mortality 0.5% (1/192).ConclusionsRTX showed effective in MOGAD, although to a lesser extent than in AQP4-IgG+NMOSD, while the safety profile warrants some caution in its prescription. Randomised-controlled trials are needed to confirm these findings and provide robust evidence to improve treatment strategies in patients with MOGAD.PROSPERO registration numberCRD42020175439.

show abstract

Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases: an Indian perspective

Cited by 6 publications

References 14 publications

Epidemiology and clinical features of demyelinating disorders in India

Epidemiology and clinical features of demyelinating disorders in India

Clinical Features and Imaging Findings of Myelin Oligodendrocyte Glycoprotein-IgG-Associated Disorder (MOGAD)

Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis

Contact Info

Product

Resources

About